Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014:88:13-36.
doi: 10.1016/B978-0-12-800148-6.00002-X.

Lipid nanoparticles for gene delivery

Yi Zhao  1 , Leaf Huang  1
Affiliations
Review

Lipid nanoparticles for gene delivery

Yi Zhao et al. Adv Genet. 2014.

Abstract

Nonviral vectors which offer a safer and versatile alternative to viral vectors have been developed to overcome problems caused by viral carriers. However, their transfection efficacy or level of expression is substantially lower than viral vectors. Among various nonviral gene vectors, lipid nanoparticles are an ideal platform for the incorporation of safety and efficacy into a single delivery system. In this chapter, we highlight current lipidic vectors that have been developed for gene therapy of tumors and other diseases. The pharmacokinetic, toxic behaviors and clinic trials of some successful lipids particles are also presented.

Keywords: Gene delivery; Lipid nanoparticles.

PubMed Disclaimer

Figures

Figure 2.1
Figure 2.1
Scheme of a lipid nanoparticle (LNP) formed by lipids (yellow), helper lipids (brown), and polyethylene glycol (PEG). Lipids condense and stabilize nucleic acids, which promote the stabilization of LNP. (See the color plate.)
Figure 2.2
Figure 2.2
A sampling of lipids as nonviral vectors for gene delivery.
See this image and copyright information in PMC

References

    1. Adrian JE, Poelstra K, Scherphof GL, Meijer DK, van Loenen-Weemaes AM, Reker-Smit C, et al. Effects of a new bioactive lipid-based drug carrier on cultured hepatic stellate cells and liver fibrosis in bile duct-ligated rats. Journal of Pharmacology and Experimental Therapeutics. 2007;321(2):536–543. http://dx.doi.org/10.1124/jpet.106.117945. - DOI - PubMed
    1. Akinc A, Goldberg M, Qin J, Dorkin JR, Gamba-Vitalo C, Maier M, et al. Development of lipidoid-siRNA formulations for systemic delivery to the liver. Molecular Therapy. 2009;17(5):872–879. http://dx.doi.org/10.1038/mt.2009.36. - DOI - PMC - PubMed
    1. Akinc A, Zumbuehl A, Goldberg M, Leshchiner ES, Busini V, Hossain N, et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nature Biotechnology. 2008;26(5):561–569. http://dx.doi.org/10.1038/Nbt1402. - DOI - PMC - PubMed
    1. Alabi CA, Love KT, Sahay G, Yin H, Luly KM, Langer R, et al. Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery. Proceedings of the National Academy of Sciences of the United States of America. 2013;110(32):12881–12886. http://dx.doi.org/10.1073/Pnas.1306529110. - DOI - PMC - PubMed
    1. Behlke MA. Chemical modification of siRNAs for in vivo use. Oligonucleotides. 2008;18(4):305–319. http://dx.doi.org/10.1089/oli.2008.0164. - DOI - PubMed

Publication types